TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China ...

Investing.com -- TD Cowen downgraded Merck & Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of ...

Investing.com -- TD Cowen downgraded Merck &Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is ...

TD Cowen initiated coverage of Repligen (RGEN) with a Buy rating and $200 price target Repligen is well positioned for “industry-leading” growth and margin expansion as it is over-indexed ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00. The company’s shares closed last Friday at $9.65.

TD Cowen lowered the firm’s price target on Neste (NTOIY) to $8 from $10 and keeps a Hold rating on the shares. The firm previewed its results and expects the company to guide to a flat year ...

TD Cowen analyst Bill Katz raised the firm’s price target on Blue Owl Capital (OWL) to $30 from $28 and keeps a Buy rating on the shares. The firm raised its estimates following Q4 results and ...

We recently compiled a list of the 11 AI News and Ratings You Shouldn't Miss. In this article, we are going to take a look at where Arm Holdings plc (NASDAQ:ARM) stands against the other AI stocks ...

Investing.com - U.S. President Donald Trump's decision to order the Treasury to cease production of the penny would likely survive judicial review, according to analysts at TD Cowen. On Sunday ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed last Friday at $0.75. Leverage the ...

TD Cowen lowered the firm’s price target on Avantor (AVTR) to $27 from $28 and keeps a Buy rating on the shares. The firm said while results and guide were a bit mixed, on the whole they portray ...